MTOR and Cowden syndrome 1: A phase II open-label clinical trial involving 18 CS patients showed that administration of oral mTOR-inhibitor (sirolimus) was tolerable in terms of its side effect profile, and was sufficient to down-regulate mTOR signaling in skin and gastrointestinal tissue [10].